Ticker Details
Viking Therapeutics, Inc. Viking Therapeutics Inc is a clinical-stage biopharmaceutical company. The company develops therapies for metabolic and endocrine disorders. It includes portfolio of five drug candidates in clinical trials or preclinical studies.
IPO Date:	April 29, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$4.05B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.46 | 3.33%
Avg Daily Range (30 D):	$0.98 | 2.98%
Avg Daily Range (90 D):	$0.92 | 2.79%

Institutional Daily Volume
Avg Daily Volume:	1.85M
Avg Daily Volume (30 D):	2.1M
Avg Daily Volume (90 D):	2.52M

Trade Size
Avg Trade Size (Sh.):	112
Avg Trade Size (Sh.) (30 D):	72
Avg Trade Size (Sh.) (90 D):	77

Institutional Trades
Total Institutional Trades:	5,148
Avg Institutional Trade:	$2.73M
Avg Institutional Trade (30 D):	$2.59M
Avg Institutional Trade (90 D):	$2.26M
Avg Institutional Trade Volume:	.1M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$6.4M
Avg Closing Trade (30 D):	$7.25M
Avg Closing Trade (90 D):	$7.21M
Avg Closing Volume:	247.67K

News

Apr 10, 2026 @ 11:30 AM Viking Therapeutics to Participate at Upcoming Inv... Source: Prnewswire

Apr 3, 2026 @ 7:26 PM Where Will Viking Therapeutics Stock Be in 10 Year... Source: Prosper Junior Bakiny

Mar 29, 2026 @ 4:30 AM 1 Reason This Biotech Stock Could Triple Before Ye... Source: Thomas Niel

Mar 26, 2026 @ 11:05 AM Viking Therapeutics Announces Completion of Enroll... Source: Prnewswire

Mar 18, 2026 @ 12:30 AM Better Weight Loss Drug Stock Buy: Eli Lilly vs Vi... Source: Adria Cimino

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-3.19	$-1.39	$-3.19
Diluted EPS	$-3.19	$-1.39	$-3.19
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-359.64M	$-157.66M	$-359.64M
Operating Income / Loss	$-393.34M	$-164.74M	$-393.34M
Cost of Revenue
Net Cash Flow	$139.14M	$65.43M	$139.14M
PE Ratio